Tim M. Mayleben
2022 - Landos Biopharma
In 2022, Tim M. Mayleben earned a total compensation of $565.9K as Former President and Chief Executive Officer; Director at Landos Biopharma, a 50% decrease compared to previous year.
Compensation breakdown
| Bonus | $275,000 |
|---|---|
| Option Awards | $9,909 |
| Salary | $236,753 |
| Other | $44,240 |
| Total | $565,902 |
Mayleben received $275K in bonus, accounting for 49% of the total pay in 2022.
Mayleben also received $9.9K in option awards, $236.8K in salary and $44.2K in other compensation.
Rankings
In 2022, Tim M. Mayleben's compensation ranked 4,140th out of 5,736 executives tracked by ExecPay. In other words, Mayleben earned more than 27.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,140 out of 5,736 | 28th |
Division Manufacturing | 2,343 out of 3,125 | 25th |
Major group Chemicals And Allied Products | 1,137 out of 1,416 | 20th |
Industry group Drugs | 1,067 out of 1,317 | 19th |
Industry Pharmaceutical Preparations | 781 out of 963 | 19th |
Source: SEC filing on April 19, 2023.
Mayleben's colleagues
We found four more compensation records of executives who worked with Tim M. Mayleben at Landos Biopharma in 2022.
News
Landos Biopharma CEO Gregory Oakes receives $1.8M in 2022
April 19, 2023
Landos Biopharma Executive Vice President of Operations Jyoti RAC's 2021 pay jumps 195% to $2.8M
April 28, 2022
Esperion Therapeutics CEO Tim Mayleben's 2021 pay rises 19% to $8.2M
April 14, 2022
Esperion Therapeutics CEO Tim Mayleben's 2019 pay falls 89% to $1.1M
April 16, 2020
Esperion Therapeutics CEO Tim Mayleben's 2018 pay jumps 94% to $9.7M
April 18, 2019